BROS vs CUE · P/E 105, rev $1.28B vs rev $9.3M
Dutch Bros Inc (BROS) versus Cue Biopharma (CUE) — a side-by-side from cached financials, not a winner call.
Dutch Bros Inc (BROS) is a restaurants company listed on NYSE.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Latest reported BROS revenue for 2024-12-31 was $1.28B. Net income was $66.5M. Revenue was up 32.6% from 2023-12-31 to 2024-12-31. BROS currently screens at market cap $11.74B and trailing P/E 105.0.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
BROS currently screens at market cap $11.74B and trailing P/E 105.0. CUE currently screens at market cap $59.5M.
Not investment advice. Open the BROS and CUE stock pages for the full models.
Not investment advice.